Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

Completed

• Conditions: Rheumatoid Arthritis; Inflammation

• Registration Number: NCT00195364
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-19
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2009-06
• Last Update Submitted: 2009-06-03
• Last Update Posted: 2009-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

• To have completed 0881A1-301-EU study in Spain
• Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.

Exclusion Criteria

• Hypersensibility to etanercept or any of its components
• Significant concurrent medical disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified